source
- FDA issues three new guidances to expand eligibility criteria for cancer trialsThe FDA's Oncology Center of Excellence has released three final guidance documents aimed at widening the pool of patients who can enroll in oncology clinical trials. The guidances focus on three…
- STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain diseaseOak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an Angelman syndrome medicine.